Chronic inflammation and the development of malignancy in the GI tract

Trends in Immunology

Volumn 36, Issue 8, 2015, Pages 451-459

  Fichtner Feigl, Stefan ^a,b   Kesselring, Rebecca ^a   Strober, Warren ^c  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b Regensburg Center of Interventional Immunology   (Germany)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZOXYMETHANE; STAT3 PROTEIN;

CANCER GROWTH; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM INFLAMMATION; EPITHELIUM CELL; GENOTOXICITY; HUMAN; MICROBIOME; MICROFLORA; NONHUMAN; REVIEW; ANIMAL; CELL TRANSFORMATION; CHRONIC DISEASE; GASTROINTESTINAL TRACT; GASTROINTESTINAL TUMOR; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CHRONIC DISEASE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84939563329     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2015.06.007     Document Type: Review

References (65)

1. Heidland A., et al. The contribution of Rudolf Virchow to the concept of inflammation: what is still of importance?. J. Nephrol. 2006, 19(Suppl. 10):S102-S109.
2. Azer S.A. Overview of molecular pathways in inflammatory bowel disease associated with colorectal cancer development. Eur. J. Gastroenterol. Hepatol. 2013, 25:271-281.
3. Myant K.B., et al. ROS production and NF-kappaB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. Cell Stem Cell 2013, 12:761-773.
4. Klampfer L. Cytokines, inflammation and colon cancer. Curr. Cancer Drug Targets 2011, 11:451-464.
5. Hussain S.P., et al. Radical causes of cancer. Nat. Rev. Cancer 2003, 3:276-285.
6. Stephens P.J., et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009, 462:1005-1010.
7. Fearon E.R. Molecular genetics of colorectal cancer. Annu. Rev. Pathol. 2011, 6:479-507.
8. Hussain S.P., et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 2000, 60:3333-3337.
9. Honjo T., et al. Molecular mechanism of class switch recombination: linkage with somatic hypermutation. Annu. Rev. Immunol. 2002, 20:165-196.
10. Conticello S.G. The AID/APOBEC family of nucleic acid mutators. Genome Biol. 2008, 9:229.
11. Matsumoto Y., et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat. Med. 2007, 13:470-476.
12. Endo Y., et al. Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers. Gastroenterology 2008, 135:889-898.
13. Takai A., et al. Targeting activation-induced cytidine deaminase prevents colon cancer development despite persistent colonic inflammation. Oncogene 2012, 31:1733-1742.
14. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128:683-692.
15. Hmadcha A., et al. Methylation-dependent gene silencing induced by interleukin 1beta via nitric oxide production. J. Exp. Med. 1999, 190:1595-1604.
16. Ushijima T., et al. Decreased fidelity in replicating CpG methylation patterns in cancer cells. Cancer Res. 2005, 65:11-17.
17. Raponi M., et al. KRAS mutations predict response to EGFR inhibitors. Curr. Opin. Pharmacol. 2008, 8:413-418.
18. Johnson S.M., et al. RAS is regulated by the let-7 microRNA family. Cell 2005, 120:635-647.
19. Shitashige M., et al. Regulation of Wnt signaling by the nuclear pore complex. Gastroenterology 2008, 134:1961-1971.
20. Shitashige M., et al. Wnt signaling inside the nucleus. Cancer Sci. 2008, 99:631-637.
21. Pritchard C.C., Grady W.M. Colorectal cancer molecular biology moves into clinical practice. Gut 2011, 60:116-129.
22. Moser A.R., et al. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990, 247:322-324.
23. Rakoff-Nahoum S., Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007, 317:124-127.
24. Neufert C., et al. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat. Protoc. 2007, 2:1998-2004.
25. Corpet D.E., Pierre F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur. J. Cancer 2005, 41:1911-1922.
26. Papanikolaou A., et al. Azoxymethane-induced colon tumors and aberrant crypt foci in mice of different genetic susceptibility. Cancer Lett. 1998, 130:29-34.
27. Papanikolaou A., et al. Initial levels of azoxymethane-induced DNA methyl adducts are not predictive of tumor susceptibility in inbred mice. Toxicol. Appl. Pharmacol. 1998, 150:196-203.
28. Nasuno M., et al. Mesenchymal stem cells cancel azoxymethane-induced tumor initiation. Stem Cells 2014, 32:913-925.
29. Takahashi M., et al. Frequent mutations of the beta-catenin gene in mouse colon tumors induced by azoxymethane. Carcinogenesis 2000, 21:1117-1120.
30. Westley C.B., et al. Enhanced acute apoptotic response to azoxymethane-induced DNA damage in the rodent colonic epithelium by Tyrian purple precursors: a potential colorectal cancer chemopreventative. Cancer Biol. Ther. 2010, 9:371-379.
31. Hu Y., et al. Absence of acute apoptotic response to genotoxic carcinogens in p53-deficient mice is associated with increased susceptibility to azoxymethane-induced colon tumours. Int. J. Cancer 2005, 115:561-567.
32. Schwitalla S., et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell 2013, 23:93-106.
33. Schwarz M., et al. Non-melanoma skin cancer in mouse and man. Arch. Toxicol. 2013, 87:783-798.
34. Normand S., et al. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:9601-9606.
35. Grivennikov S., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
36. Wu S., et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat. Med. 2009, 15:1016-1022.
37. Han W., Lo H.W. Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett. 2012, 318:124-134.
38. Boccaccio C., et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 1998, 391:285-288.
39. Bollrath J., et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102.
40. Phesse T.J., et al. Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt-beta-catenin-mediated intestinal tumor growth and regeneration. Sci. Signal. 2014, 7:ra92.
41. Becker C., et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004, 21:491-501.
42. low macrophages. J. Clin. Invest. 2011, 121:1692-1708.
43. Heinrich P.C., et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
44. Waldner M.J., et al. Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development. Semin. Immunol. 2014, 26:75-79.
45. Chalaris A., et al. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. Dig. Dis. 2012, 30:492-499.
46. Iliopoulos D., et al. An epigenetic switch involving NF-kappaB, Lin28, Let-7 microRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139:693-706.
47. Putoczki T.L., et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 2013, 24:257-271.
48. Ernst M., et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J. Clin. Invest. 2008, 118:1727-1738.
49. Grivennikov S.I., et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012, 491:254-258.
50. Dumoutier L., et al. New activation modus of STAT3: a tyrosine-less region of the interleukin-22 receptor recruits STAT3 by interacting with its coiled-coil domain. J. Biol. Chem. 2009, 284:26377-26384.
51. Lim C., Savan R. The role of the IL-22/IL-22R1 axis in cancer. Cytokine Growth Factor Rev. 2014, 25:257-271.
52. Kirchberger S., et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J. Exp. Med. 2013, 210:917-931.
53. Wang L., et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 2009, 206:1457-1464.
54. Murray P.J. The JAK-STAT signaling pathway: input and output integration. J. Immunol. 2007, 178:2623-2629.
55. Min/+ mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int. J. Cancer 2006, 118:25-34.
56. Yang L., Pei Z. Bacteria, inflammation, and colon cancer. World J. Gastroenterol. 2006, 12:6741-6746.
57. Garrett W.S., et al. Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. Cancer Cell 2009, 16:208-219.
58. -/- ulcerative colitis: the role of T-bet as a peacekeeper of host-commensal relationships. Cytokine 2009, 48:144-147.
59. Min mouse: independence from the microbial and natural killer (beige locus) status. Cancer Res. 1997, 57:812-814.
60. -/- mice. Gastroenterology 2014, 147:667-679.
61. Arthur J.C., et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012, 338:120-123.
62. Cuevas-Ramos G., et al. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11537-11542.
63. Nougayrede J.P., et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 2006, 313:848-851.
64. Barnich N., et al. CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J. Clin. Invest. 2007, 117:1566-1574.
65. Barker N., et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009, 457:608-611.